Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.87 USD | -1.74% | +2.37% | -12.44% |
Financials (USD)
Sales 2024 * | 512M | Sales 2025 * | 627M | Capitalization | 3.48B |
---|---|---|---|---|---|
Net income 2024 * | -560M | Net income 2025 * | -476M | EV / Sales 2024 * | 6.26 x |
Net cash position 2024 * | 274M | Net cash position 2025 * | 337M | EV / Sales 2025 * | 5.01 x |
P/E ratio 2024 * |
-6.38
x | P/E ratio 2025 * |
-8.01
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.55% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | -1.74% | ||
1 week | +2.37% | ||
Current month | -1.57% | ||
1 month | -1.18% | ||
3 months | -14.41% | ||
6 months | +4.75% | ||
Current year | -12.44% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | +0.15% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 41.87 | -1.74% | 802,954 |
24-05-16 | 42.61 | +3.62% | 1,194,745 |
24-05-15 | 41.12 | +0.37% | 674,823 |
24-05-14 | 40.97 | +0.02% | 564,473 |
24-05-13 | 40.96 | +0.15% | 440,612 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.44% | 3.48B | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.47% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- RARE Stock